Chad M. VanDenBerg, PharmD, BCPP
- 5Articles
- 16.3KReads
- 2012Active
- 6Collaborators
- 66Citations
About
Chad M. VanDenBerg, PharmD, BCPP, has published research focused on the use of monoamine oxidase inhibitors (MAOIs) in the treatment of major depressive disorder (MDD), with particular attention to transdermal delivery systems. His work explores clinical approaches to depression and patient care, contributing to discussions on innovative pharmacological methods. VanDenBerg collaborated with co-authors including David A. Flockhart and Larry Culpepper in articles published in 2012.
Publications
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
